Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

48.38 +0.79 (+1.66%)

Streaming Delayed Price Updated: 10:51 AM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

34 35 Next >

Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry ↗

December 21, 2023

Which weight-loss stocks are good buys today?

Via The Motley Fool

Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug ↗

December 21, 2023

The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy...

Via Benzinga

This Big Pharma Is Teaming Up With Nvidia to Make Drugs With AI. Here's What You Need to Know ↗

December 20, 2023

It isn't the first drugmaker to partner with the chipmaker, and it won't be the last.

Via The Motley Fool

Topics Artificial Intelligence

FDA Grants Priority Review to Xolair (omalizumab) for Children and Adults With Food Allergies Based on Positive National Institutes of Health Phase III Study Results

December 19, 2023

From Genentech

Via Business Wire

Weight-Loss Drug Gold Rush Gets Larger As New Player Fractyl Health Files For $100M IPO ↗

December 15, 2023

Fractyl Health, developing procedural and gene therapies for type 2 diabetes and obesity, filed an S-1 filing with the SEC on Thursday to raise up to $100 million in an initial public offering.

Via Benzinga

Topics Regulatory Compliance

The 3 Most Undervalued Biotech Stocks to Buy in December ↗

December 15, 2023

Biotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks.

Via InvestorPlace

Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease

December 14, 2023

From Roivant Sciences

Via GlobeNewswire

Can Altimmune's weight-loss drug be a game-changer?

December 14, 2023

The runaway success of weight-loss drugs like Novo Nordisk A/S (NYSE: NVO) Ozempic and Eli Lilly and Co. (NYSE: LLY) Mounjaro has kicked off a gold

Via MarketBeat

Poseida Therapeutics' New Treatment For Multiple Myeloma Shows Early Success In Clinical Trial ↗

December 11, 2023

Poseida Therapeutics Inc (NASDAQ: PSTX) released early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen...

Via Benzinga

New Data for Genentech’s Columvi and Lunsumio Presented at ASH 2023 Support Continued Benefit for People With Lymphoma

December 10, 2023

From Genentech

Via Business Wire

New Data Reinforce the Benefit of Early Preventative Treatment With Genentech’s Hemlibra (emicizumab-kxwh) for Babies With Severe hemophilia A

December 09, 2023

From Genentech

Via Business Wire

Genentech’s Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

December 08, 2023

From Genentech

Via Business Wire

Genentech’s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment

December 08, 2023

From Genentech

Via Business Wire

Why Viking Therapeutics Was Crushing It This Week ↗

December 08, 2023

Nowadays, it's good to be a developer of next-generation weight loss drugs.

Via The Motley Fool

JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities ↗

December 06, 2023

Johnson & Johnson (NYSE: JNJ) has no immediate plans to venture into weight-loss drugs due to the existing competition saturation, as Chief Executive Officer

Via Benzinga

While Pfizer Faced A Setback, Altimmune, Roche And Mainz Biomed Advanced in The Battle Against Obesity And Colorectal Cancer ↗

December 05, 2023

Obesity has been linked to development of a range of diseases and unfortunately, cancer. More specifically, the National Cancer Institute estimated that colorectal cancer is 1.3 times more likely in...

Via Benzinga

Roche's Combination Therapy Shows Improved Progression Free Survival In Certain Breast Cancer With Mutation ↗

December 05, 2023

Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance) and fulvestrant as a potenti

Via Benzinga

Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

December 05, 2023

From Genentech

Via Business Wire

Jim Cramer Highlights 'Transformational' Impact Of Weight Loss Drugs Like Ozempic: Focus Now On 'Potential Winners' From The Same Narrative ↗

December 04, 2023

Via Benzinga

Roche Stock Rises On $3.1 Billion Deal For Obesity Drugmaker ↗

December 04, 2023

Roche said it will spend up to $3.1 billion to acquire Carmot Therapeutics, a biotech firm developing obesity drugs. Roche stock gained on the news.

Via Investor's Business Daily

Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs ↗

December 04, 2023

Roche Holding AG (OTC: RHHBY) has agreed to

Via Benzinga

AstraZeneca Strikes Deal With Absci To Leverage AI In Cancer Drug Discovery: Report ↗

December 04, 2023

AstraZeneca plc (NASDAQ: AZN) has reportedly finalized a partnership deal valued at up to $247 million with Absci Corporation (NASDAQ: ABSI), a U.S.-based firm specializing in artificial intelligence...

Via Benzinga

Topics Artificial Intelligence

Ignore Crypto: These Stocks Could Make You Rich ↗

November 23, 2023

Investing in solid, growing businesses is a less risky road to riches than investing in Bitcoin or other cryptocurrencies.

Via The Motley Fool

Genentech and NVIDIA Enter Into Strategic AI Research Collaboration to Accelerate Drug Discovery and Development

November 21, 2023

From Genentech

Via Business Wire

Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare ↗

November 17, 2023

Are you looking for biotech breakthrough stocks? Here are three revolutionary stocks redefining healthcare.

Via InvestorPlace

FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca ↗

November 16, 2023

The FDA approved Bristol Myers Squibb And Co's (NYSE: BMY) Augtyro (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small

Via Benzinga

Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030

November 14, 2023

EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END

Via FinancialNewsMedia

The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks? ↗

November 10, 2023

The real competitive battle is about to begin, and it will last a long time.

Via The Motley Fool

BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake ↗

November 07, 2023

The company's recently FDA-approved gene therapy is struggling to gain traction.

Via Investor's Business Daily

Regeneron's Skin Drugs Propel Revenue In Q3, Witnesses Strong Demand For Higher Dose Version Of Flagship Eye Drug ↗

November 02, 2023

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned Q3 adjusted EPS of $11.59, up 4% Y/Y, beating the $10.77 Street estimate

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.